📰 Amanda Cray News
Amanda Cray News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Amanda Cray. Real-time updates on events, politics, business and more.
May 29, 2024
HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines,...
April 26, 2024
HAMILTON, ON and BOSTON, April 25, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that
April 25, 2024
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as...
April 25, 2024
HAMILTON, ON and BOSTON, April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates as precision medicines,...
February 7, 2024
HAMILTON, ON and BOSTON, Feb. 6, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the
February 6, 2024
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
January 4, 2024
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant...
November 9, 2023
HAMILTON, ON and BOSTON, Nov. 8, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the
November 8, 2023
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...
November 7, 2023
Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study...